T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.95% |
| 2 | Consumer Discretionary | 13.63% |
| 3 | Financials | 12.8% |
| 4 | Industrials | 12.27% |
| 5 | Technology | 9.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1376
Boise Cascade
BCC
$2.91B
| $7.3M | ﹤0.01% |
255,025
-240,155
| -48% | -$6.41M |
|
1377
GameStop
GME
$8.36B
| $7.29M | ﹤0.01% |
721,040
-114,000
| -14% | -$1.12M |
|
|
GLOP
1378
DELISTED
GASLOG PARTNERS LP
GLOP
| $7.28M | ﹤0.01% |
+200,000
| New | +$5.89M |
|
1379
Walker & Dunlop
WD
$1.47B
| $7.27M | ﹤0.01% |
514,953
-7,600
| -1% | -$116K |
|
1380
Dr. Reddy's Laboratories
RDY
$10.2B
| $7.21M | ﹤0.01% |
835,030
+79,915
| +11% | +$672K |
|
1381
ATI
ATI
$30.9B
| $7.2M | ﹤0.01% |
159,631
-3,500
| -2% | -$143K |
|
|
FLIR
1382
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $7.19M | ﹤0.01% |
207,110
+7,600
| +4% | +$266K |
|
1383
TriplePoint Venture Growth BDC
TPVG
$220M
| $7.12M | ﹤0.01% |
434,600
+5,600
| +1% | +$86.6K |
|
|
MDVN
1384
DELISTED
MEDIVATION, INC.
MDVN
| $7.08M | ﹤0.01% |
183,740
+9,224
| +5% | +$311K |
|
1385
DNOW Inc
DNOW
$2.98B
| $7.03M | ﹤0.01% |
+194,039
| New | +$6.68M |
|
|
BZC
1386
DELISTED
BREEZE-EASTERN CORPORATION COM
BZC
| $7.01M | ﹤0.01% |
549,760
-4,127
| -0.7% | -$44.5K |
|
|
VJET
1387
DELISTED
VOXELJET AG American Depositary Shares (each representing one Ordinary Share)
VJET
| $6.93M | ﹤0.01% |
66,232
-540
| -0.8% | -$43.6K |
|
1388
Watts Water Technologies
WTS
$12.8B
| $6.91M | ﹤0.01% |
111,890
-400,140
| -78% | -$23M |
|
1389
Diageo
DEO
$53.1B
| $6.9M | ﹤0.01% |
54,215
+600
| +1% | +$75.6K |
|
|
CNVR
1390
DELISTED
CONVERSANT INC COM STK (DE)
CNVR
| $6.9M | ﹤0.01% |
271,591
+17,100
| +7% | +$427K |
|
1391
Hyster-Yale Materials Handling
HY
$616M
| $6.89M | ﹤0.01% |
77,794
-1,200
| -2% | -$109K |
|
|
AUY
1392
DELISTED
Yamana Gold, Inc.
AUY
| $6.86M | ﹤0.01% |
831,873
-1,244,627
| -60% | -$9.77M |
|
|
CYBE
1393
DELISTED
Cyberoptics Corp
CYBE
| $6.85M | ﹤0.01% |
857,630
-600
| -0.1% | -$4.78K |
|
|
BIG
1394
DELISTED
Big Lots, Inc.
BIG
| $6.85M | ﹤0.01% |
149,900
+10,100
| +7% | +$411K |
|
|
HCBK
1395
DELISTED
HUDSON CITY BANCORP INC
HCBK
| $6.84M | ﹤0.01% |
695,389
| – | – |
|
|
SWI
1396
DELISTED
SOLARWINDS INC COM STK (DE)
SWI
| $6.83M | ﹤0.01% |
176,600
+20,300
| +13% | +$811K |
|
|
XRM
1397
DELISTED
Xerium Technologies Inc (new)
XRM
| $6.82M | ﹤0.01% |
488,200
+228,200
| +88% | +$3.15M |
|
|
BTU
1398
DELISTED
PEABODY ENERGY CORP COM STK NEW (DE)
BTU
| $6.81M | ﹤0.01% |
27,769
+334
| +1% | +$86.9K |
|
1399
Nasdaq
NDAQ
$54.2B
| $6.74M | ﹤0.01% |
523,770
| – | – |
|
1400
Liberty Media Series A
FWONA
$24.1B
| $6.7M | ﹤0.01% |
275,842
-1,338,226
| -83% | -$30.7M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.